Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
110 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2016', provides in depth analysis on Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted pipeline therapeutics. The report provides comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects - The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Overview 10 Therapeutics Development 11 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Stage of Development 11 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Therapy Area 12 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Indication 13 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Companies 17 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Products under Development by Universities/Institutes 21 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment 23 Assessment by Monotherapy/Combination Products 23 Assessment by Mechanism of Action 24 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development 29 Akari Therapeutics, Plc 29 Alexion Pharmaceuticals Inc 30 Alnylam Pharmaceuticals, Inc. 31 Amgen Inc. 32 Epirus Biopharmaceuticals, Inc. 33 F. Hoffmann-La Roche Ltd. 34 InflaRx GmbH 35 Novartis AG 36 Noxxon Pharma AG 37 Ophthotech Corp. 38 Ra Pharmaceuticals, Inc. 39 Swedish Orphan Biovitrum AB 40 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles 41 AcPepA - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ALN-CC5 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 ALXN-1007 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 ALXN-1210 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 ALXN-5500 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 avacincaptad pegol sodium - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Bikaciomab - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 BikajuMab - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Coversin - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Coversin LA - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 eculizumab - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 eculizumab biosimilar - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 eculizumab biosimilar - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 IFX-1 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 IFX-2 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Mubodina - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 NM-9405 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 NOXD-19 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 NOXD-20 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 NOXD-21 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 Protein to Inhibit Complement C5 for Immunology - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 RA-101295 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 RA-101348 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 RA-101495 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 RO-7112689 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 SOBI-005 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Synthetic Peptide to Inhibit Complement C5 for Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Autoimmune Disorders - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 tesidolumab - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects 91 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products 94 Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Featured News & Press Releases 95 Sep 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal Hemoglobinuria 95 Aug 29, 2016: European Commission Grants Orphan Drug Designation to ALXN1007 for the Treatment of Patients with Graft-Versus-Host Disease 95 Jul 13, 2016: Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency to Conduct Phase 2 Trial in Paroxysmal Nocturnal Hemoglobinuria 96 Jul 12, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Paroxysmal Nocturnal Hemoglobinuria 96 Jul 07, 2016: New Data from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis Presented at ICNMD Annual Congress 97 Jul 06, 2016: Federal Court Dismisses Challenge to Constitutionality of Federal Government's Drug Price Watchdog 99 Jul 06, 2016: Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin 99 Jun 11, 2016: Alnylam Reports Initial ALN-CC5 Results in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from Ongoing Phase 1/2 Study 100 Jun 10, 2016: Alexion Pharmaceuticals Presented data on ALXN1007 at 21st Congress of the European Hematology Association 102 Jun 10, 2016: Late-Breaking Data Presented at EHA: All Patients with PNH Treated with Once-Monthly Dosing of ALXN1210 in Phase 1/2 Study Exhibit Rapid and Sustained Reductions in LDH 103 Jun 10, 2016: Ra Pharmaceuticals Presents Clinical Data on Complement C5 Inhibitor RA101495 at the 21st Congress of the European Hematology Association 104 Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery 105 Jun 06, 2016: Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris) in Patients with Refractory Generalized Myasthenia Gravis (gMG) 106 Jun 03, 2016: Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data 108 Jun 01, 2016: European Commission Grants Orphan Drug Designation to ALXN1210 for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) 108 Appendix 109 Methodology 109 Coverage 109 Secondary Research 109 Primary Research 109 Expert Panel Validation 109 Contact Us 109 Disclaimer 110
List of Tables
Number of Products under Development for, H2 2016 11 Number of Products under Development by Therapy Area, H2 2016 12 Number of Products under Development by Indication, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Early Stage Products, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 18 Products under Development by Companies, H2 2016 (Contd..1) 19 Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2016 21 Products under Investigation by Universities/Institutes, H2 2016 22 Assessment by Monotherapy/Combination Products, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Pipeline by Akari Therapeutics, Plc, H2 2016 29 Pipeline by Alexion Pharmaceuticals Inc, H2 2016 30 Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 31 Pipeline by Amgen Inc., H2 2016 32 Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 33 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34 Pipeline by InflaRx GmbH, H2 2016 35 Pipeline by Novartis AG, H2 2016 36 Pipeline by Noxxon Pharma AG, H2 2016 37 Pipeline by Ophthotech Corp., H2 2016 38 Pipeline by Ra Pharmaceuticals, Inc., H2 2016 39 Pipeline by Swedish Orphan Biovitrum AB, H2 2016 40 Dormant Projects, H2 2016 91 Dormant Projects (Contd..1), H2 2016 92 Dormant Projects (Contd..2), H2 2016 93 Discontinued Products, H2 2016 94
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
